Volume 27, Number 6—June 2021
Dispatch
Ebola Virus IgG Seroprevalence in Southern Mali
Sidy Bane, Kyle Rosenke, Ousmane Maiga, Friederike Feldmann, Kimberly Meade-White, Julie Callison, David Safronetz, Nafomon Sogoba, and Heinz Feldmann
Table
Results of EBOV serology on 600 human samples from southern Mali*
| Location | No. (%) positive |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EBOV GP IgG |
EBOV NP IgG |
Both |
|||||||||
| 1:100 | 1:400 | 1:1,600 | 1:100 | 1:400 | 1:1,600 | 1:100 | 1:400 | 1:1,600 | |||
| Bamba | 23 (11.5) | 2 (1.0) | 0 | ND | 6 (3.0) | 2 (1.0) | NA | 1 (0.5) | 0 | ||
| Banzana | 39 (19.5) | 9 (4.5) | 1 (0.5) | ND | 5 (2.5) | 0 | NA | 2 (1.0) | 0 | ||
| Soromba |
60 (30.0) |
11 (5.5) |
0 |
ND |
13 (6.5) |
2 (1.0) |
NA |
6 (3.0) |
0 |
||
| Total | 122 (20.3) | 22 (3.7) | 1 (0.2) | ND | 24 (4.0) | 4 (0.7) | NA | 9 (1.5) | 0 | ||
*A total of 200 samples were tested from each location. EBOV, Ebola virus; GP, glycoprotein. NA, not applicable; ND, not done; NP, nucleoprotein.
Page created: April 21, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.